Vanguard Capital Management Establishes 5.19% Passive Stake in United Therapeutics Corp

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, reporting a new 5.19% stake in United Therapeutics Corp (UTHR). As of the event date on March 31, 2026, Vanguard beneficially owns 2,278,348 shares of Common Stock. The filing indicates that Vanguard holds sole dispositive power over all 2,278,348 shares, while maintaining sole voting power over 320,809 shares. There is no shared voting or dispositive power reported. This position represents a significant increase from a previously reported 0% ownership, crossing the 5% threshold that triggers a Schedule 13G filing for passive investors. The filing was made under Rule 13d-1(b), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reporting person includes various Vanguard affiliates and business divisions, such as Vanguard Asset Management Limited and Vanguard Global Advisers, LLC, in accordance with SEC disaggregation guidelines. No other single person's interest in these securities exceeds 5%.